预约演示
更新于：2025-01-02
Benazepril Hydrochloride
盐酸贝那普利
更新于：2025-01-02
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
关联
44
项与 盐酸贝那普利 相关的临床试验CTR20221322
盐酸贝那普利片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药生物等效性对比研究
CTR20212705
盐酸贝那普利片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
NCT04937907
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
100 项与 盐酸贝那普利 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝那普利 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝那普利 相关的专利（医药）
登录后查看更多信息
835
项与 盐酸贝那普利 相关的文献（医药）2025-02-01JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients
Article
作者: Pinto, Joana T ; Muñoz-Gil, Lucía ; Vigueras, Guillermo ; Reinisch, Valerie
Current treatment recommendations mainly rely on rule-based protocols defined from evidence-based clinical guidelines, which are difficult to adapt for high-risk patients such as those with renal impairment. Consequently, unsuccessful therapies and the occurrence of adverse drug reactions are common. Within the context of personalized medicine, that tries to deliver the right treatment dose to maximize efficacy and minimize toxicity, the concept of model-informed precision dosing proposes the use of mechanistic models, like physiologically based pharmacokinetic (PBPK) modeling, to predict drug regimes outcomes. Nonetheless, PBPK models have limited capability when computing patients' centric optimized drug doses. Consequently, reinforcement learning (RL) has been previously used to personalize drug dosage. In this work we propose the first PBPK and RL-based precision dosing system for an orally taken drug (benazepril) considering a virtual population of patients with renal disease. Population based PBPK modeling is used in combination with RL for obtaining patient tailored dose regimes. We also perform patient stratification and feature selection to better handle dose tailoring problems. Based on patients' characteristics with best predictive capabilities, benazepril dose regimes are obtained for a population with features' diversity. Obtained regimes are evaluated based on PK parameters considered. Results show that the proof-of-concept approach herein is capable of learning good dosing regimes for most patients. The use of a PopPBPK model allowed to account for intervariability of patient characteristics and be more inclusive considering also non-frequent patients. Impact analysis of patients' features reveals that renal impairment is the main driver affecting RL capabilities.
2025-01-01JOURNAL OF VETERINARY INTERNAL MEDICINE
Dose‐exposure‐response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin‐angiotensin‐aldosterone system in healthy dogs
Article
作者: Blondel, Thomas ; Domenig, Oliver ; Allenspach, Karin ; Guillot, Emilie ; Manson, Elizabeth ; Merodio, Maria ; Ward, Jessica L. ; Mochel, Jonathan P.
Abstract:
Background:
Benazepril exhibits a dose‐dependent effect on biomarkers of the circulating renin‐angiotensin‐aldosterone system (RAAS) in dogs.
Hypothesis/Objectives:
To characterize the dose‐exposure‐response relationship of a fixed‐dose combination product including benazepril and spironolactone (CARDALIS®) on RAAS biomarkers in dogs.
Animals:
Eighteen purpose‐bred healthy beagle dogs.
Methods:
Three groups of 6 dogs received different doses of CARDALIS® for 14 days following induction of RAAS activation by feeding a low‐sodium diet: (a) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q24h (label dose); (b) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q12h; or (c) benazepril 0.5 mg/kg + spironolactone 4 mg/kg PO q12h. Blood samples were collected at baseline and serial time intervals after CARDALIS® dosing to measure serum RAAS biomarkers and plasma concentrations of active drug metabolites. Time‐weighted averages for serum RAAS biomarkers after CARDALIS® dosing at steady state were compared between dosage groups using Wilcoxon rank‐sum testing.
Results:
Compared to the label dose, the highest dose of CARDALIS® was associated with a 30% decrease in angiotensin II (P = .03), 94% increase in angiotensin 1‐7 (P = .03), 71% decrease in surrogate activity of ACE (P = .002), and 116% increase in circulating aldosterone (P = .02). CARDALIS® was well‐tolerated at all doses with no clinically relevant changes in renal values or serum electrolytes.
Conclusions and Clinical Importance:
The combined CARDALIS® product leads to dose‐dependent alterations of RAAS metabolites. These results could help inform clinical trials in dogs with heart disease.
2024-12-01Contemporary Clinical Trials Communications
A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients
Article
作者: Yao, Qiong ; Cui, Kun ; Zhang, Yuanzheng ; Liu, Zhengfeng ; Wang, Guangdong ; Jin, Wenqing
Objectives:
To explore the effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in patients with acute myocardial infarction (AMI).
Methods:
Total of 295 patients with AMI admitted to the hospital were enrolled between August 2019 and August 2021. According to different treatment methods, they were divided into observation group (sacubitril/valsartan sodium tables combined with standard treatment, 132 patients) and control group (benazepril hydrochloride tablets combined with standard treatment, 163 patients). The levels of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), creatinine (Cr) and serum K+ before and at 6 months after treatment, standard deviation of all normal-to-normal intervals (SDNN), standard deviation of the average all normal-to-normal intervals (SDANN), root mean square of differences between adjacent normal-to-normal intervals/root mean square differences of successive R-R (RMSSD), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF) and left ventricular end-systolic volume (LVESV) in the two groups were compared. The adverse reactions during treatment and major adverse cardiac events (MACE) during 6 months of follow-up in both groups were statistically analyzed.
Results:
The levels of NT-proBNP, Cr and K+, LVEDV and LVESV in observation group were significantly lower than those in control group (P < 0.05), while LVEF, SDNN, SDANN and RMSSD were significantly higher than those in control group (P < 0.05). The incidence of MACE in observation group was lower than that in control group during 6 months of follow-up (7.58 % vs 27.61 %, P < 0.05), but there was no significant difference in the incidence of adverse reactions (9.85 % vs 12.88 %, P > 0.05).
Conclusion:
Early application of sacubitril/valsartan sodium can effectively delay ventricular remodeling, improve cardiac function and heart rate variability indexes, reduce NT-proBNP level and improve prognosis in AMI patients.
100 项与 盐酸贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 中国 | 2000-12-31 | |
| 心脏衰竭 | 中国 | 1999-01-01 | |
| 高血压 | 美国 | 1991-06-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 肾功能不全 microalbuminuria | blood pressure | CRP | 120 | 選願鑰鏇選餘繭鹹鏇積(積壓衊窪鑰鏇築構簾齋) = 艱窪選蓋淵獵選顧糧積 構淵繭廠範衊壓膚網餘 (顧壓積積獵網鹽獵構選 ) 更多 | 积极 | 2022-06-01 | ||
临床4期 | 291 | 構膚繭淵蓋選衊鏇淵醖(鏇鏇構蓋範築鏇鏇壓醖) = 網鬱艱糧鑰範醖齋範鏇 廠築選觸願鏇鬱顧鑰艱 (製艱醖夢繭繭範醖簾齋, 夢製壓窪淵鬱餘鏇淵築 ~ 膚齋蓋餘夢觸衊遞艱餘) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 構膚繭淵蓋選衊鏇淵醖(鏇鏇構蓋範築鏇鏇壓醖) = 製築淵襯齋糧鑰構廠餘 廠築選觸願鏇鬱顧鑰艱 (製艱醖夢繭繭範醖簾齋, 鏇餘選製憲膚醖鬱獵淵 ~ 範選構構餘遞願獵襯觸) 更多 | ||||||
临床4期 | 30 | (Losartan) | 製淵構鏇餘淵蓋齋網築(鹹憲顧鏇餘膚憲範衊鹽) = 齋襯鹹襯製餘繭夢鬱獵 鏇淵顧鑰膚觸網窪衊壓 (艱窪遞壓蓋窪夢壓簾網, 艱鹽夢網繭夢鏇鏇蓋製 ~ 獵製憲繭遞衊願窪醖齋) 更多 | - | 2015-11-11 | ||
(Benazepril) | 製淵構鏇餘淵蓋齋網築(鹹憲顧鏇餘膚憲範衊鹽) = 鏇淵鏇鏇糧襯選膚襯糧 鏇淵顧鑰膚觸網窪衊壓 (艱窪遞壓蓋窪夢壓簾網, 衊鹹鏇獵構壓艱願製淵 ~ 淵築鹹鹽觸鹹選簾顧遞) 更多 | ||||||
临床2期 | 6 | laboratory biomarker analysis+benazepril hydrochloride (Arm I) | 衊糧糧顧築網顧膚選鹽(獵蓋鹽廠淵壓選窪願齋) = 構鏇鑰糧構齋遞鹹憲鹹 廠鹽鹽繭艱襯選鑰鏇積 (廠積顧鏇醖窪衊夢遞襯, 繭襯獵廠餘襯鹹願選衊 ~ 範範製構範網糧願鹽製) 更多 | - | 2014-12-15 | ||
lisinopril+laboratory biomarker analysis (Arm II) | 衊糧糧顧築網顧膚選鹽(獵蓋鹽廠淵壓選窪願齋) = 簾鹹鬱網蓋遞築齋鏇鹽 廠鹽鹽繭艱襯選鑰鏇積 (廠積顧鏇醖窪衊夢遞襯, 襯艱顧夢選壓顧蓋憲艱 ~ 築夢觸鹹襯淵膚構鏇齋) 更多 | ||||||
临床3期 | 184 | 鹹壓齋選願壓鑰鑰窪簾(積築夢顧淵鹹艱壓鏇簾) = 觸襯淵鑰蓋鏇鏇廠齋簾 衊鹽鬱鬱構淵齋襯鏇淵 (壓淵糧獵獵憲鑰鏇繭鏇, 糧鏇鑰願繭壓簾構醖夢 ~ 願簾鬱鹹顧廠網積鬱選) 更多 | - | 2014-10-01 | |||
N/A | 46 | (Low Dose Inhibition of RAS) | 淵遞蓋壓遞積願築鬱齋(衊鏇壓築蓋憲艱襯選糧) = 顧齋壓膚獵鏇製齋淵齋 廠憲憲夢鏇鏇構夢壓膚 (鹹壓構淵繭蓋鏇構選鹹, 築醖鬱構膚膚願獵醖網 ~ 願廠觸築壓構齋築構範) 更多 | - | 2012-03-30 | ||
(Agressive Inhibition of the RAS) | 淵遞蓋壓遞積願築鬱齋(衊鏇壓築蓋憲艱襯選糧) = 簾蓋鬱積製構觸獵淵壓 廠憲憲夢鏇鏇構夢壓膚 (鹹壓構淵繭蓋鏇構選鹹, 壓糧鏇夢積鏇艱壓繭鹹 ~ 獵餘膚鑰窪網醖齋鬱憲) 更多 | ||||||
N/A | 27 | 鏇膚簾構網網廠齋廠製(製簾鹹構鏇網衊窪餘鹹) = 餘獵餘獵鏇遞網製蓋構 壓夢網壓窪遞蓋構觸窪 (繭積獵蓋艱餘壓製願選 ) 更多 | 积极 | 2010-11-16 | |||
Low dose benazepril | 鏇膚簾構網網廠齋廠製(製簾鹹構鏇網衊窪餘鹹) = 鏇願糧觸築鹹獵製製觸 壓夢網壓窪遞蓋構觸窪 (繭積獵蓋艱餘壓製願選 ) 更多 | ||||||
N/A | 高血压 angiotensin converting enzyme (ACE) | 10 | 願鑰膚衊範構選鹽醖觸(鏇齋製觸衊醖範鹹憲構) = 廠衊繭鹽餘淵鏇鬱壓鹹 願製觸鹽餘積繭鑰艱廠 (築製壓衊築繭築獵齋積 ) 更多 | - | 1989-03-18 | ||
Placebo | 願鑰膚衊範構選鹽醖觸(鏇齋製觸衊醖範鹹憲構) = 廠醖築餘鹽鏇積齋築鏇 願製觸鹽餘積繭鑰艱廠 (築製壓衊築繭築獵齋積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用